Rain Therapeutics is focused on developing innovative, targeted therapies for cancer patients, particularly those with genetically identifiable tumors that are likely to benefit from specific treatments. Their lead product candidate, milademetan (RAIN-32), is an oral small molecule inhibitor that targets the MDM2-p53 interaction, which plays a crucial role in various malignancies. Milademetan is currently in clinical development for patients with MDM2-dependent cancers that have wild-type TP53, including advanced liposarcoma and other solid tumors. The company is conducting multiple clinical trials, including the MANTRA trial, which aims to compare the efficacy and safety of milademetan against the standard treatment, trabectedin, in patients with unresectable or metastatic dedifferentiated liposarcoma.

The clinical trials for milademetan are designed to assess various endpoints, such as progression-free survival and overall survival, while also evaluating the safety profile and management of adverse events. Rain Therapeutics emphasizes the importance of genetic profiling in selecting patients for their therapies, aiming to enhance the quality of life for those with significant unmet medical needs in oncology. By focusing on precision medicine, Rain is committed to advancing its clinical development programs to bring transformative therapies to market for cancer patients.

United States

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Cancer

Rain Therapeutics

Solid tumor/s

<p class="font_8">Rain’s lead product candidate, RAIN-32 (milademetan), a small &nbsp;molecule, oral inhibitor of mouse double minute 2 (MDM2) is being &nbsp;developed in patients with MDM2 amplified or overexpressed cancers. MDM2 &nbsp;is a critical regulator of tumor protein 53 (p53), which is known as &nbsp;the “guardian of the genome.” p53 regulates the cell cycle, and in that &nbsp;role is essential for tumor suppression. If MDM2 is overexpressed, p53 &nbsp;can be inactivated, leading to tumor growth and cancer progression. By &nbsp;inhibiting MDM2, RAIN-32 is expected to reactivate p53, which can resume &nbsp;its role in controlling cancer growth. RAIN-32’s differentiated profile &nbsp;enables a rationally-designed dosing schedule that we believe has the &nbsp;potential to reduce toxicities while preserving activity.</p>

Rain Therapeutics

Company Details